Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8516578 | 1.00 | PDK1 (0.45) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL28113274 | 1.00 | PDK1 (0.45) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL361957 | 0.98 | PDK1 (0.44) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL21032274 | 0.83 | PDK1 (0.36) | PDK1PDK2PDK3PDK4POLB | |
| SCHEMBL2031558 | 0.81 | PKM (0.45) | MAPTPKMKDM4ECYP4F2CYP4A11 | |
| SCHEMBL776033 | 0.79 | PKM (0.44) | POLBNPSR1MAPTHIF1APKM | |
| SCHEMBL9420020 | 0.79 | CYP4F2 (0.42) | POLBNPSR1MAPTHIF1APKM | |
| SCHEMBL12555522 | 0.79 | CYP4F2 (0.42) | POLBNPSR1MAPTHIF1APKM | |
| SCHEMBL11659039 | 0.79 | POLB (0.49) | POLBNPSR1MAPTHIF1APKM | |
| SCHEMBL4427462 | 0.78 | MMP8 (0.47) | POLBNPSR1MAPTHIF1APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345746-A1 | Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patents | NOVARTIS AG (CH) | 2020-11-05 | — | — | US | disclosed |
| US-10722518-B2 | Oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy | NOVARTIS AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10683287-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| US-20200048237-A1 | A Free Base Oxazine Derivative in Crystalline Form | NOVARTIS AG (CH) | 2020-02-13 | — | — | US | disclosed |
| US-20200048236-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2020-02-13 | — | — | US | disclosed |
| EP-3525793-A1 | AN OXAZINE DERIVATIVE FOR USE IN THE TREATMENT OR PREVENTION OF CEREBRAL AMYLOID ANGIOPATHY | Novartis AG (CH) | 2019-08-21 | — | — | EP | disclosed |
| WO-2019142111-A1 | SALT FORMS OF AN OXAZINE DERIVATIVE BACE INHIBITOR | NOVARTIS AG (CH) | 2019-07-25 | — | — | WO | disclosed |
| EP-3487504-A1 | AN OXAZINE DERIVATIVE FOR USE IN THE PREVENTION OF ALZHEIMER'S DISEASE IN AT RISK PATIENTS | Novartis AG (CH) | 2019-05-29 | — | — | EP | disclosed |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-10035794-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-07-19 | — | — | US | disclosed |
| WO-2012095451-A1 | CRYSTALLINE OXAZINE DERIVATIVE AND ITS USE AS BACE INHIBITOR | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| US-20120178745-A1 | Novel Crystalline Oxazine Derivative | NOVARTIS PHARMA AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-8207164-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20110160477-A1 | Process for Producing alpha-Trifluoromethyl-alpha,beta-Unsaturated Ester | Central Glass Company ,Limited (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2332902-A1 | PROCESS FOR PRODUCING -TRIFLUOROMETHYL- , -UNSATURATED ESTER | Central Glass Company, Limited (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-4701569-A | PERFLUOROALKYLATION OF CARBONYL COMPOUNDS IN PRESENCE OF ZINC IN ABSENCE OF ULTRASONIC WAVES | RHONE-POULENC SPECIALTIES CHIMIQUES (FR) | 1987-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048237-A1 | A Free Base Oxazine Derivative in Crystalline Form | APP, PSEN1, MAPT | PDK1 3696/4885PDK2 2404/4885PDK3 2489/4885 |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | OTC, GRIK5, GRIN2C | PDK1 1332/4885PDK2 849/4885PDK3 1102/4885 |
| US-20110160477-A1 | Process for Producing alpha-Trifluoromethyl-alpha,beta-Unsaturated Ester | DEGS1, DHCR24, FDFT1 | PDK1 2799/4885PDK2 839/4885PDK3 2220/4885 |
| US-20120178745-A1 | Novel Crystalline Oxazine Derivative | CYP3A5, CHRM5, CYP2C8 | PDK1 2857/4885PDK2 1806/4885PDK3 1373/4885 |
| US-10683287-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | PDK1 650/4885PDK2 569/4885PDK3 1114/4885 |
| US-20200048236-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | PDK1 566/4885PDK2 558/4885PDK3 1055/4885 |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | PDK1 650/4885PDK2 569/4885PDK3 1114/4885 |
| US-10035794-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | PDK1 650/4885PDK2 569/4885PDK3 1114/4885 |
| US-10722518-B2 | Oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy | BACE1, APP, PSEN1 | PDK1 4314/4885PDK2 3440/4885PDK3 3600/4885 |
| US-20200345746-A1 | Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patents | BACE1, BACE2, PSEN1 | PDK1 2401/4885PDK2 2182/4885PDK3 2704/4885 |
| US-20120184539-A1 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders | BACE2, BACE1, PSEN2 | PDK1 566/4885PDK2 558/4885PDK3 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.